ABSTRACT Botrocetin, originally called venom coagglutinin, is a Bothrops factor that causes aggregation of blood platelets in the presence of the von Willebrand component of the factor VIII macromolecular complex. The complex consists of a series of multimers with a molecular weight of about 1-20 x 106. Ristocetin, another agent that causes platelet aggregation dependent on von Willebrand factor, reacts with only the higher molecular weight multimers. We report on the reactivity of botrocetin in relation to the multimeric structure of the factor VIII complex. Several plasmas or plasma fractions with abnormal distribution of the multimeric sizes were examined, including variant von Willebrand disease type HA with lack of the higher molecular weight forms, commercial antihemophilic factor concentrates with a preponderance of lower molecular weight forms, cryoprecipitate-free plasma containing mainly the smaller multimers, and a chromatographic fraction of plasma containing only the highest molecular weight polymers. Factor VIII-related antigen content was adjusted to 25-100%. All of the preparations lacking the high molecular weight forms caused prompt platelet aggregation with botrocetin, but none of them caused aggregation in the ristocetin test made isochronal with the botrocetin test. The very high molecular weight polymers were equally effective with botrocetin and ristocetin. These findings indicate that the Bothrops factor is reactive with a broad spectrum of high to low molecular weight forms of the factor VIII complex, suggesting that bioassays of von Willebrand factor with botrocetin should correlate better with immunoassays for factor VIII-related antigen and could reflect better the full platelet-aggregating function of the complex than do ristocetin determinations.
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A factor found in the venom of several snakes, mainly in the Bothrops species, has been shown to be a unique "activator" of the platelet aggregation reaction that is dependent on the von Willebrand factor (vWF). vWF, named because of its absence in the severe form of the inherited bleeding disorder "designated von Willebrand disease (vWD)," is part of the factor VIII macromolecular complex. The complex possesses two types of biological activities. One is the antihemophilic factor (AHF) or coagulant factor VIII (factor VIII:C) activity which corrects the bleeding defect in hemophilia A. The other type is vWF activities (factor VIIIR:vWF) which correct the platelet-related functional defect in vWD. These two types of activities of the complex can be measured immunologically and are designated as the factor VIII coagulant antigen (factor VIII:CAg) and the factor VIII-related antigen (factor VIIIR:Ag), respectively. The complex in normal plasma consists of a series of macromolecular polymers of molecular weights ranging from about 106 to 20 X 106.
The uniqueness of the venom factor, originally called "venom coagglutinin (VCA)" and more recently called "botrocetin," is that at present it is the only material that can be used to identify and quantify the platelet-aggregating vWF regardless of its mammalian source (1, 2). Both ristocetin, the other known type of activator of vWF-dependent platelet aggregation, and botrocetin can be used to measure vWF activity in human plasma (3), but vWF in most mammalian plasmas is resistant to ristocetin (2, 4). Ristocetin is known to cause platelet aggregation with only the larger polymers or multimers of the factor VIII macromolecular complex (5) (6) (7) (8) (9) . This has led to the concept that the platelet-aggregating function of the complex resides primarily in the high molecularweight multimers of factor VIIIR:Ag. Thus, plasmas from certain of the variants of vWD, known as type IIA (6, 7, (10) (11) (12) which lack the highest molecular weight multimers, do not aggregate platelets with ristocetin yet have nearly normal or higher than normal levels of factor VIIIR:Ag. Furthermore, the supernatant plasma remaining after the removal of cryoprecipitate contains mainly the lower molecular weight multimers of factor VIIIR:Ag and does not aggregate platelets in the presence of ristocetin (7, 10, 12, 13) .
The above observations led us to study the reactivity of botrocetin with a number of plasmas or plasma preparations with an abnormal distribution of factor VIIIR:Ag multimers to determine if the pattern of reactivity of botrocetin was restricted to the high molecular weight multimers as with ristocetin or if it reacted with a broader spectrum of the polymers of the factor VIII complex. The factor VIII macromolecular preparations studied contained either (i) a predominance of the lower molecular weight multimers with marked reduction or absence of the higher molecular weight forms or (ii) only the highest molecular weight polymers with absence of the smaller multimeric types. It was found that botrocetin induced platelet aggregation with all of the preparations tested, including those that were inactive with ristocetin. Thus, botrocetin is also unique in respect to its platelet-aggregating ability with the whole spectrum of factor VIIIR:Ag multimers.
MATERIALS AND METHODS Materials. Ristocetin (Lundberg, Copenhagen) was dissolved in isotonic saline at the desired concentration. Botrocetin was prepared from the venom of Bothropsjararaca as described (1) and was assayed for potency in units per ml (14) . One unit of botrocetin is defined as that amount in 1 ml that causes aggregation of lyophilized platelets in 14 sec in a standardized procedure (14) . The stock solution of botrocetin (500 units/ml) was diluted with imidazole-buffered saline. Lyophilized human platelets (15) were made from a blood bank platelet concentrate 72 hr old (16) with fixation in paraformaldehyde (17) . The rabbit Abbreviations: vWF, von Willebrand factor; vWD, von Willebrand disease; AHF, antihemophilic factor; factor VIII:C, coagulant factor VIII; factor VIIIR:Ag, factor VIII-related antigen; factor VIII:CAg, factor VIII coagulant antigen.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. antiserum to human factor VIIIR:Ag and its preparation have been described (12) . Cryosupernatant was cryoprecipitate-free human plasma (16) . Cryoprecipitate (16) Fig. 1 that human reference plasma serially diluted caused platelet aggregation at nearly the same rate with the adjusted concentrations of ristocetin and botrocetin (Fig. 1) (-) . Test mixtures: for ristocetin testing, 0.18 ml of 0.084 M imidazole-buffered saline (pH 7.35), 0.1 ml of plasma (1:4) or concentrate (25% factor VIIIR:Ag), 0.1 ml of lyophilized platelets (800,000/mm3), and 0.02 ml of ristocetin (20 mg/ml); for botrocetin testing, 0.19 ml of buffer, 0.1 ml of plasma or concentrate, 0.1 ml of platelets, and 0.01 ml of botrocetin (500 units/ml). (3) . Two-dimensional crossed immunoelectrophoresis demonstrated the lack of the high molecular weight multimers in the plasmas of two subjects with variant vWD. This is a confirmation of similar data on these two plasmas previously reported (12) . These plasmas were inactive in the ristocetin screening test for vWF. Thus, they lacked the so-called ristocetin cofactor. However, both plasmas caused prompt platelet aggregation with botrocetin. These findings suggest that botrocetin testing would be a valuable additional diagnostic procedure for detecting type IIA vWD.
Although extremely rich in factor VIII:C activity, the commercial factor VIII concentrate has a greatly reduced content of the higher molecular weight multimers of factor VIIIR:Ag (Table 1) (12, 18) and is relatively ineffective in correcting the prolonged bleeding time in severe vWD (19) . When the concenMedical Sciences: Brinkhous et al.
trate was sufficiently diluted, it caused no platelet aggregation with ristocetin, a finding in keeping with the depletion of high molecular weight multimers. Platelet aggregation was prompt with botrocetin.
The last of the three preparations with depleted high molecular weight multimers of factor VIIIR:Ag was the cryosupernatant harvested in the preparation of therapeutic cryoprecipitate concentrates of AHF (factor VIII:C). The smaller molecular weight multimers mainly go into solution when frozen plasma is thawed at 4TC, but only limited amounts of larger molecular weight multimers are solubilized. The ristocetin test was negative, as expected, but the botrocetin test resulted in platelet aggregation. The above group of experiments demonstrate that the lower molecular weight multimers of factor VIIIR:Ag are capable of causing prompt platelet aggregation with botrocetin.
The last experiment in this study was designed to test whether botrocetin was reactive with the highest molecular weight multimers of factor VIIIR:Ag, as is ristocetin. It has been demonstrated by Sepharose column chromatography of cryoprecipitate that the first eluates contain only the highest molecular weight multimers (8, 20) . We took advantage of this phenomenon and tested the early elution fractions for platelet-aggregating vWF with both ristocetin and botrocetin ( Table 2 ). The fractions caused prompt platelet aggregation with both reagents, and aggregation times were approximately the same in the two tests. In the first fraction, the botrocetin-induced aggregation time was somewhat shorter than that with ristocetin. Thus, it is concluded that botrocetin is reactive with the highest molecular weight multimers of factor VIIIR:Ag.
In spite of the heterogeneity of factor VIIIR:Ag in plasma and plasma fractions as well as the lack of reactivity or the mass of smaller macromolecules with ristocetin, botrocetin was found to be effective with the full range of sizes of the factor VIIIR:Ag multimers in inducing platelet aggregation. This implies that a correlation between vWF bioassay values with botrocetin and immunoelectrophoretic determination of factor VIIIR:Ag should be better than is the case for ristocetin assays. "Ristocetin cofactor" is a term frequently used for the high molecular weight multimers of factor VIIIR:Ag that cause platelet aggregation with ristocetin. If one wanted an analogous term for the multimers that cause platelet aggregation with botrocetin it would be "botrocetin cofactor." Botrocetin cofactor values could be a better indicator of the total potential platelet-aggregating activity of plasma vWF than are ristocetin cofactor values.
